Parr Mcknight Wealth Management Group LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,065 shares of the company's stock, valued at approximately $608,000.
Other hedge funds have also recently made changes to their positions in the company. Grassi Investment Management purchased a new position in Novo Nordisk A/S in the fourth quarter valued at about $215,000. Nisa Investment Advisors LLC raised its stake in shares of Novo Nordisk A/S by 36.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,500 shares of the company's stock worth $129,000 after acquiring an additional 400 shares in the last quarter. SG Americas Securities LLC boosted its stake in Novo Nordisk A/S by 379.8% in the fourth quarter. SG Americas Securities LLC now owns 107,725 shares of the company's stock valued at $9,267,000 after acquiring an additional 85,272 shares in the last quarter. Avior Wealth Management LLC increased its position in Novo Nordisk A/S by 13.9% during the 4th quarter. Avior Wealth Management LLC now owns 20,597 shares of the company's stock valued at $1,772,000 after buying an additional 2,511 shares in the last quarter. Finally, Red Door Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S by 167.3% during the fourth quarter. Red Door Wealth Management LLC now owns 9,608 shares of the company's stock valued at $826,000 after acquiring an additional 6,013 shares in the last quarter. Institutional investors own 11.54% of the company's stock.
Novo Nordisk A/S Price Performance
Shares of NYSE:NVO traded down $1.91 during midday trading on Wednesday, reaching $68.53. 4,364,515 shares of the company's stock traded hands, compared to its average volume of 6,702,805. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a fifty day simple moving average of $65.91 and a two-hundred day simple moving average of $82.38. The company has a market cap of $307.55 billion, a P/E ratio of 20.85, a PEG ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on NVO. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Moderate Buy" and an average target price of $135.00.
Get Our Latest Research Report on NVO
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
